No headlines found.
AgeX Therapeutics Reports Fourth Quarter and Annual 2023 Financial Results
Globe Newswire (Fri, 22-Mar 5:27 PM ET)
SHAREHOLDER UPDATE: Halper Sadeh LLC Investigates AGE, GRPH, FIXX
PRNewswire (Tue, 27-Feb 8:52 PM ET)
Business Wire (Tue, 27-Feb 3:19 PM ET)
AgeX Therapeutics Inc is a biotechnology company engaged in the development and commercialization of novel therapeutics targeting human aging. The firm through its PureStem and induced Tissue Regeneration (iTR) technologies develops medicines designed to address some of the unsolved problems in aging. Its PureStem-derived cell-based therapeutic candidates in development are AGEX-VASC1, AGEX-BAT1 and AGEX-iTR1547.
Agex Therapeutics trades on the AMEX stock market under the symbol AGE.
As of April 17, 2024, AGE stock price was flat at $11.10 with million shares trading.
AGE has a beta of -2.86, meaning it tends to be less sensitive to market movements. AGE has a correlation of 0.01 to the broad based SPY ETF.
AGE has a market cap of $27.76 million. This is considered a Sub-Micro Cap stock.
In the last 3 years, AGE stock traded as high as $22.32 and as low as $.31.
AGE has outperformed the market in the last year with a price return of +1716.7% while the SPY ETF gained +23.0%. AGE has also outperformed the stock market ETF in the last 3 month and 2 week periods returning +2696.0% and 0.0%, respectively, while the SPY returned +5.7% and -3.5%, respectively.
AGE support price is $10.16 and resistance is $12.05 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that AGE stock will trade within this expected range on the day.